{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:19:29Z","timestamp":1787987969040,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2021YFA1101700, 2022YFE0118000"],"award-info":[{"award-number":["2021YFA1101700, 2022YFE0118000"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030049, 32027802"],"award-info":[{"award-number":["82030049, 32027802"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82394433, 82361148130"],"award-info":[{"award-number":["82394433, 82361148130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00259-026-07989-x","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:45:29Z","timestamp":1781567129000},"page":"6264-6273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline amyloid deposition phenotypes inform the spatial distribution of early amyloid clearance with lecanemab in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"53","author":[{"given":"Xiaofeng","family":"Dou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4084-5150","authenticated-orcid":false,"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chentao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"7989_CR1","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/S0140-6736(24)01883-X","volume":"404","author":"MT Heneka","year":"2024","unstructured":"Heneka MT, Morgan D, Jessen FJTL. Passive anti-amyloid \u03b2 immunotherapy in Alzheimer\u2019s disease\u2014opportunities and challenges. Lancet. 2024;404:2198\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(24)01883-X.","journal-title":"Lancet"},{"key":"7989_CR2","doi-asserted-by":"publisher","unstructured":"Albertini G, Zielonka M, Cuypers M-L, Snellinx A, Xu C, Poovathingal S, et al. The Alzheimer\u2019s therapeutic Lecanemab attenuates A\u03b2 pathology by inducing an amyloid-clearing program in microglia. Nat Neurosci. 2025;1\u201311. https:\/\/doi.org\/10.1038\/s41593-025-02125-8.","DOI":"10.1038\/s41593-025-02125-8"},{"key":"7989_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"7989_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.14283\/jpad.2023.123","volume":"3","author":"S Cohen","year":"2023","unstructured":"Cohen S, van Dyck C, Gee M, Doherty T, Kanekiyo M, Dhadda S, et al. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized. J Prev Alzheimers Dis. 2023;3:771\u20137. https:\/\/doi.org\/10.14283\/jpad.2023.123.","journal-title":"J Prev Alzheimers Dis"},{"key":"7989_CR5","doi-asserted-by":"publisher","unstructured":"Li L-L, Wang R-Z, Wang Z, Hu H, Xu W, Zhu L, et al. Safety and short-term outcomes of lecanemab for Alzheimer\u2019s disease in China: a multicentre study. Brain. 2025;awaf427. https:\/\/doi.org\/10.1093\/brain\/awaf427.","DOI":"10.1093\/brain\/awaf427"},{"key":"7989_CR6","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1097\/CM9.0000000000003888","volume":"138","author":"W Kang","year":"2025","unstructured":"Kang W, Gao C, Li X, Wang X, Zhong H, Wei Q, et al. Safety and effectiveness of lecanemab in Chinese patients with early Alzheimer\u2019s disease: Evidence from a multidimensional real-world study. Chin Med J (Engl). 2025;138:2907\u201316. https:\/\/doi.org\/10.1097\/CM9.0000000000003888.","journal-title":"Chin Med J (Engl)"},{"key":"7989_CR7","doi-asserted-by":"publisher","unstructured":"van Dyck CH, Sperling R, Johnson K, Dhadda S, Kanekiyo M, Li D et al. Long-term safety and efficacy of lecanemab in early Alzheimer\u2019s disease: Results from the clarity AD open\u2010label extension study. 2025;21:e70905. https:\/\/doi.org\/10.1002\/alz.70905","DOI":"10.1002\/alz.70905"},{"key":"7989_CR8","doi-asserted-by":"publisher","unstructured":"Chiotis K, Wang Y, La Joie R, Rabinovici, GDJJonmop, Society of Nuclear Medicine. The Role of Amyloid-\u03b2 and Tau PET in the New Era of Alzheimer Disease Therapies. J Nucl Med. 2025;jnumed. https:\/\/doi.org\/10.2967\/jnumed.124.268339.","DOI":"10.2967\/jnumed.124.268339"},{"key":"7989_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003. e4.","journal-title":"Alzheimers Dement"},{"key":"7989_CR10","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvad\u00f3 G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49:3508\u201328. https:\/\/doi.org\/10.1007\/s00259-022-05784-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7989_CR11","doi-asserted-by":"publisher","first-page":"103765","DOI":"10.1016\/j.nicl.2025.103765","volume":"46","author":"L Iaccarino","year":"2025","unstructured":"Iaccarino L, Burnham SC, Tunali I, Wang J, Navitsky M, Arora AK, et al. A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research. Neuroimage Clin. 2025;46:103765. https:\/\/doi.org\/10.1016\/j.nicl.2025.103765.","journal-title":"Neuroimage Clin"},{"key":"7989_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41398-023-02328-2","volume":"13","author":"Y Sun","year":"2023","unstructured":"Sun Y, Zhao Y, Hu K, Wang M, Liu Y, Liu B, et al. Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals. Transl Psychiatry. 2023;13:35. https:\/\/doi.org\/10.1038\/s41398-023-02328-2.","journal-title":"Transl Psychiatry"},{"key":"7989_CR13","doi-asserted-by":"publisher","first-page":"e1692","DOI":"10.1212\/WNL.0000000000200148","volume":"98","author":"LE Collij","year":"2022","unstructured":"Collij LE, Salvad\u00f3 G, Wottschel V, Mastenbroek SE, Schoenmakers P, Heeman F, et al. Spatial-temporal patterns of \u03b2-amyloid accumulation: a subtype and stage inference model analysis. Neurology. 2022;98:e1692\u2013703. https:\/\/doi.org\/10.1212\/WNL.0000000000200148.","journal-title":"Neurology"},{"key":"7989_CR14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00415-015-7732-5","volume":"262","author":"TD Singh","year":"2015","unstructured":"Singh TD, Josephs KA, Machulda MM, Drubach DA, Apostolova LG, Lowe VJ, et al. Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. J Neurol. 2015;262:1483\u201392. https:\/\/doi.org\/10.1007\/s00415-015-7732-5.","journal-title":"J Neurol"},{"key":"7989_CR15","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease. Alzheimer\u2019s Association Workgr. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimer\u2019s Association Workgr"},{"key":"7989_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(11)70289-7","volume":"11","author":"SJ Crutch","year":"2012","unstructured":"Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NCJTLN. Posterior cortical atrophy. Lancet Neurol. 2012;11:170\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(11)70289-7.","journal-title":"Lancet Neurol"},{"key":"7989_CR17","doi-asserted-by":"publisher","first-page":"A42","DOI":"10.1136\/jnnp-2024-ABN.137","volume":"95","author":"S Marwan","year":"2024","unstructured":"Marwan S, David L, Shobha D, Michael I, Steven H, Luigi G, et al. ARIA by clinical diagnosis and baseline amyloid PET levels: a subgroup analysis of clarity AD. J Neurol Neurosurg Psychiatry. 2024;95:A42. . https:\/\/doi.org\/10.1136\/jnnp-2024-ABN.137","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7989_CR18","doi-asserted-by":"publisher","unstructured":"Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, et al. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025;82:19\u201329. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3937%.","DOI":"10.1001\/jamaneurol.2024.3937%"},{"key":"7989_CR19","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1038\/s41467-018-05892-0","volume":"9","author":"AL Young","year":"2018","unstructured":"Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat Commun. 2018;9:4273. https:\/\/doi.org\/10.1038\/s41467-018-05892-0.","journal-title":"Nat Commun"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07989-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07989-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07989-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:01:09Z","timestamp":1787986869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07989-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7989"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07989-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the ethics committees and review board of the Second Affiliated Hospital of Zhejiang University School of Medicine approved the study (No. 2025\u2009\u2212\u20091515). The requirement to obtain informed consent was waived.","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}